Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was down 2.2% on Tuesday . The company traded as low as $0.88 and last traded at $0.87. Approximately 1,615 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 614,173 shares. The stock had previously closed at $0.89.

A number of equities research analysts have recently weighed in on TTPH shares. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Piper Jaffray Companies cut their price objective on Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, March 15th. Gabelli lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 price objective on the stock. in a research report on Friday, March 15th. ValuEngine lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 6th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $4.08.

The company has a quick ratio of 7.10, a current ratio of 7.28 and a debt-to-equity ratio of 0.53. The stock has a market cap of $47.70 million, a price-to-earnings ratio of -0.64 and a beta of 2.85.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.93 million. On average, equities analysts forecast that Tetraphase Pharmaceuticals Inc will post -1.52 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new stake in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $33,000. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $69,000. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its position in shares of Tetraphase Pharmaceuticals by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 71,000 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 16,300 shares in the last quarter. Institutional investors own 42.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.mareainformativa.com/news/2019/05/16/tetraphase-pharmaceuticals-ttph-trading-down-2-2.html.

Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Lock-Up Period Expiration

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.